Description
1000mg – 2000mg of Full Spectrum CBD + other Terpenes and 1500mg Boswellia per ounce. Full spectrum, also called “whole plant”, means the full plant extract is included.Federal Farm Bill compliant, contains less than 0.3% THC. See more at CBD Info and COAs below.
Boswellia, also known as Frankincense, comes from the Boswellia Serrata tree, native to India. The resinous part of Boswellia Serrata possesses monoterpenes, diterpenes, triterpenes, tetracyclic triterpenic acids and four major pentacyclic triterpenic acids i.e. boswellic acid, acetyl-boswellic acid, 11-keto-boswellic acid and acetyl-11-keto-boswellic acid.
Ingredients
1. 1000mg – 2000mg Full Spectrum CBD plus other Terpenes per ounce (see full list of cannabinoids and terpenes below)
2. Organic Medium-Chain Triglycerides (MCT) Coconut Oil
3. 1500mg Boswellia (Frankincense) per ounce
We strongly encourage you to do additional research to determine which CBD products are best for you. Due to FDA regulations, we cannot share all of the benefits of cannabidiol, but we can link to reputable, third-party resources that can. The links below will open up sites outside of hellobluecbd.com in a new tab. If you have any questions, please don’t hesitate to click the blue bubble in the lower right corner to chat with us, or send a message through our contact page.
The Endocannabinoid System
Pacher P, Bátkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006;58(3):389-462. doi:10.1124/pr.58.3.2
Anxiety Relief
Blessing EM, Steenkamp MM, Manzanares J, Marmar CR. Cannabidiol as a Potential Treatment for Anxiety Disorders. Neurotherapeutics. 2015;12(4):825-836. doi:10.1007/s13311-015-0387-1
Bergamaschi MM, Queiroz RH, Chagas MH, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology. 2011;36(6):1219-1226. doi:10.1038/npp.2011.6
Crippa JA, Guimarães FS, Campos AC, Zuardi AW. Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age. Front Immunol. 2018;9:2009. Published 2018 Sep 21. doi:10.3389/fimmu.2018.02009
Pain Relief
Ryz NR, Remillard DJ, Russo EB. Cannabis Roots: A Traditional Therapy with Future Potential for Treating Inflammation and Pain. Cannabis Cannabinoid Res. 2017;2(1):210-216. Published 2017 Aug 1. doi:10.1089/can.2017.0028
Topical Applications (Muscle Butter)
Chen J, Jiang QD, Chai YP, Zhang H, Peng P, Yang XX. Natural Terpenes as Penetration Enhancers for Transdermal Drug Delivery. Molecules. 2016;21(12):1709. Published 2016 Dec 11. doi:10.3390/molecules21121709
Sports Performance
McCartney D, Benson MJ, Desbrow B, Irwin C, Suraev A, McGregor IS. Cannabidiol and Sports Performance: a Narrative Review of Relevant Evidence and Recommendations for Future Research. Sports Med Open. 2020;6(1):27. Published 2020 Jul 6. doi:10.1186/s40798-020-00251-0
General Use in Therapy and Psychiatry
Calapai G, Mannucci C, Chinou I, et al. Preclinical and Clinical Evidence Supporting Use of Cannabidiol in Psychiatry. Evid Based Complement Alternat Med. 2019;2019:2509129. Published 2019 Aug 29. doi:10.1155/2019/2509129
Elsaid S, Kloiber S, Le Foll B. Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings. Prog Mol Biol Transl Sci. 2019;167:25-75. doi: 10.1016/bs.pmbts.2019.06.005. Epub 2019 Aug 28. PMID: 31601406.
Bonaccorso S, Ricciardi A, Zangani C, Chiappini S, Schifano F. Cannabidiol (CBD) use in psychiatric disorders: A systematic review. Neurotoxicology. 2019 Sep;74:282-298. doi: 10.1016/j.neuro.2019.08.002. Epub 2019 Aug 11. PMID: 31412258.
Mandolini GM, Lazzaretti M, Pigoni A, Oldani L, Delvecchio G, Brambilla P. Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview. Epidemiol Psychiatr Sci. 2018 Aug;27(4):327-335. doi: 10.1017/S2045796018000239. Epub 2018 May 23. PMID: 29789034; PMCID: PMC6998871.
Calapai G, Mannucci C, Chinou I, et al. Preclinical and Clinical Evidence Supporting Use of Cannabidiol in Psychiatry. Evid Based Complement Alternat Med. 2019;2019:2509129. Published 2019 Aug 29. doi:10.1155/2019/2509129
Reviews
There are no reviews yet.